Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study

Background: In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, atorvastatin 80 mg/day reduced the risk of stroke in patients with recent stroke or TIA. Post hoc analysis found this overall benefit included an increase in the numbers of treated patients having hemorrhagic stroke (n = 55 for active treatment vs n = 33 for placebo). Methods: We explored the relationships between hemorrhage risk and treatment, baseline patient characteristics, most recent blood pressure, and most recent low-density lipoprotein (LDL) cholesterol levels prior to the hemorrhage. Results: Of 4,731 patients, 67% had ischemic strokes, 31% TIAs, and 2% hemorrhagic strokes as entry events. In addition to atorvastatin treatment (HR 1.68, 95% CI 1.09 to 2.59, p = 0.02), Cox multivariable regression including baseline variables significant in univariable analyses showed that hemorrhagic stroke risk was higher in those having a hemorrhagic stroke as the entry event (HR 5.65, 95% CI 2.82 to 11.30, p < 0.001), in men (HR 1.79, 95% CI 1.13 to 2.84, p = 0.01), and with age (10y increments, HR 1.42, 95% CI 1.16 to 1.74, p = 0.001). There were no statistical interactions between these factors and treatment. Multivariable analyses also found that having Stage 2 (JNC-7) hypertension at the last study visit before a hemorrhagic stroke increased risk (HR 6.19, 95% CI 1.47 to 26.11, p = 0.01), but there was no effect of most recent LDL-cholesterol level in those treated with atorvastatin. Conclusions: Hemorrhagic stroke was more frequent in those treated with atorvastatin, in those with a hemorrhagic stroke as an entry event, in men, and increased with age. Those with Stage 2 hypertension at the last visit prior to the hemorrhagic stroke were also at increased risk. Treatment did not disproportionately affect the hemorrhagic stroke risk associated with these other factors. There were no relationships between hemorrhage risk and baseline low-density lipoprotein (LDL) cholesterol level or recent LDL cholesterol level in treated patients.

[1]  J. Farmer.  High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[2]  D. Lawlor,et al.  Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study , 2006, BMJ : British Medical Journal.

[3]  A. Algra,et al.  Predictors of risk of intracerebral haemorrhage in patients with a history of TIA or minor ischaemic stroke , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[5]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[6]  S. Yokoyama,et al.  HMG-CoA Reductase Inhibitor Protects Against In Vivo Arterial Thrombosis by Augmenting Platelet-Derived Nitric Oxide Release in Rats , 2005, Journal of cardiovascular pharmacology.

[7]  P. Touboul,et al.  Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.

[8]  C. Cannon,et al.  Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation , 2004, Journal of Thrombosis and Thrombolysis.

[9]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[10]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[11]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[12]  A. Algra,et al.  Risk Factors for Intracerebral Hemorrhage in the General Population: A Systematic Review , 2003, Stroke.

[13]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[14]  P. Libby,et al.  Effects of statins in reducing thrombotic risk and modulating plaque vulnerability , 2003, Clinical cardiology.

[15]  J. Mehta,et al.  Anti-thrombotic Effects of Atorvastatin-An Effect Unrelated to Lipid Lowering , 2002, Journal of cardiovascular pharmacology and therapeutics.

[16]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[17]  P. Austin,et al.  Rate of stroke recurrence in patients with primary intracerebral hemorrhage. , 2000, Stroke.

[18]  D. Albanes,et al.  Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. , 1999, Stroke.

[19]  Kyeong-Seok Lee,et al.  Recurrence of Bleeding in Patients with Hypertensive Intracerebral Hemorrhage , 1999, Cerebrovascular Diseases.

[20]  S. Ibayashi,et al.  Blood pressure control and recurrence of hypertensive brain hemorrhage. , 1998, Stroke.

[21]  P. Allhoff,et al.  The Honolulu Heart Program , 1991 .

[22]  D. Reed,et al.  Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. , 1989, Stroke.

[23]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.